The biotechnology industry in the U.S. is facing serious decline due to China’s strategic focus on emulating successful ecosystems like Boston’s. Recent findings indicate that nearly half of large pharmaceutical licensing deals involve Chinese firms, with about $136 billion in transactions projected for 2025. In response, bipartisan efforts, such as the Biotech Investment National Security Act, aim to protect U.S. investments in biotechnology and prevent the outsourcing of crucial innovations to foreign adversaries. Emphasizing the importance of biotechnology for national security and economic growth, experts stress the need for continued investment in research and local capacities to maintain competitiveness.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.bostonglobe.com/2026/06/09/opinion/massachusetts-biotech-china/
